How is AOD-9604 administered?
This describes how AOD-9604 is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once daily, fasted schedule, generally over 8-12 weeks. Specific dosing is individual and beyond general information, and human evidence for AOD-9604 is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once daily, fasted
- Cycle length: 8-12 weeks
- Half-life: ~30 minutes
References
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone — Ng FM, Sun J, Sharma L, et al., Hormone Research, 2000
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice — Heffernan M, Summers RJ, Thorburn A, et al., Endocrinology, 2001
- Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans — Stier H, Vos E, Kenley D, Journal of Endocrinology and Metabolism, 2013;3(1-2):7-15
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on AOD-9604
Last updated 2026-06-15.